

Q326 Financial Results

October 29, 2026

Forward-Looking Statements

Statements included in this presentation that are not historical in nature are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Gilead cautions readers that forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include those relating to: Gilead's ability to achieve its full year 2026 financial guidance and future projected financial results; impacts resulting from regulatory or legislative policies or processes, including the impact from pricing reform in the Inflation Reduction Act (such as Medicare part D Pricing reform and Biktarvy Maximum Fair Price determination), the expiration of subsidies related to the Affordable Care Act, our most-favored-nation pricing agreement with the U.S. government and tariffs; Gilead's ability to make progress on any of its long-term ambitions or priorities laid out in its corporate strategy; Gilead's ability to accelerate or sustain revenues for its virology, oncology, inflammation and other programs; Gilead's ability to manage, execute and realize the potential benefits of acquisitions, collaborations or licensing arrangements, including the announced PepStar acquisition; the risk that Gilead's U.S. manufacturing and R&D investment may not achieve their intended benefits; patent protection and estimated loss of exclusivity for our products and product candidates; Gilead's ability to initiate, progress or complete clinical trials within currently anticipated timeframes or at all, the possibility of unfavorable results from ongoing and additional clinical trials, including those involving anito-cel, emvistegrast, lenacapavir and HCXT-2001 (such as PURPOSE-365 and SWIFT), and the risk that safety and efficacy data from clinical trials may not warrant further development of Gilead's product candidates or the product candidates of Gilead's strategic partners; Gilead's ability to resolve the issues cited by the FDA in pending clinical holds to the satisfaction of the FDA and the risk that FDA may not remove such clinical holds, in whole or in part, in a timely manner or at all; Gilead's ability to submit new drug applications for new product candidates or expanded indications in the currently anticipated timelines; Gilead's ability to receive or maintain regulatory approvals in a timely manner or at all, including with respect to anito-cel, and the risk that any such approvals, if granted, may be subject to significant limitations on use and may be subject to withdrawal or other adverse actions by the applicable regulatory authority; Gilead's ability to successfully commercialize its products; the risk of potential disruptions to the manufacturing and supply chain of Gilead's products; pricing and reimbursement pressures from government agencies and other third parties, including required rebates and other discounts; a larger than anticipated shift in payer mix to more highly discounted payer segments; market share and price erosion caused by the introduction of generic versions of Gilead products; the risk that physicians and patients may not see advantages of Gilead's products over other therapies, including Bixlenvo and Trodelvy; Gilead's ability to effectively manage, execute and realize the anticipated benefits of the access strategy relating to lenacapavir for HIV PrEP, including voluntary licensing arrangements and external partnerships relating to lenacapavir; and other risks identified from time to time in Gilead's reports filed with the SEC, including annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. In addition, Gilead makes estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures. Gilead bases its estimates on historical experience and on various other market specific and other relevant assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. There may be other factors of which Gilead is not currently aware that may affect matters discussed in the forward-looking statements and may also cause actual results to differ significantly from these estimates. Further, results for the quarter ended September 30, 2026 are not necessarily indicative of operating results for any future periods. Gilead directs readers to its press releases, annual reports on Form 10-K, quarterly reports on Form 10-Q and other subsequent disclosure documents filed with the SEC. Gilead claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements.

Gilead owns or has rights to various trademarks, copyrights and trade names used in its business, including the following: GILEAD®, GILEAD SCIENCES®, KITE®, AMBISOME®, ATRIPLA®, BIKTARVY®, BIXLENVO™, CAYSTON®, COMPLERA®, DESCOVY®, DESCOVY FOR PREP®, EMTRIVA®, EPCLUSA®, EVIPLERA®, GENVOYA®, HARVONI®, HEPCLUDEX®, JYSELECA®, LETAIRIS®, LIVDELZI®/LYVDELZI®, ODEFSEY®, SOVALDI®, STRIBILD®, SUNLENCA®, TECARTUS®, TRODELVY®, TRUVADA®, TRUVADA FOR PREP®, TYBOST®, VEKLURY®, VEMLIDY®, VIREAD®, VOSEVI®, YESCARTA®, YEZTUGO®/YEYTUO® and ZYDELIG®. This presentation may also refer to trademarks, service marks and trade names of other companies.



Contents

Key Takeaways

4-5

Commercial Results

6-14

Pipeline Updates

15-20

Financial Results

21-27

Appendix

29-36



Q326 Key Takeaways

Daniel O'Day

Chairman & Chief Executive Officer



Gilead Q326 - Key Takeaways

1 Business Performance

- Total Q326 Base Business up 16% YoY; strongest growth in over 10 years, driven by HIV, Trodelvy, and Livedelzi
- Total Q326 HIV up 18% YoY; Biktarvy up 10% YoY, with all-time high U.S. Tx market share; PrEP grew ~2x YoY
- Oncology up 9% YoY, driven by Trodelvy growth across metastatic breast cancer
- FY26 Base Business expected to grow 10-11% YoY; FY26 HIV now expected to grow 12% YoY

2 Clinical Updates

- Promising Phase 2 SWIFT data for emvistegrast ($\alpha 4\beta 7$) in ulcerative colitis shared at UEGW 2026
- 2H26 Inflammation updates expected for edecesertib (IRAK4) in CLE and gangertamig (BCMA TCE)
- Initiated two Phase 2 trials, PULSAR 1 and 2, evaluating injectable GS-3242 (INSTI) plus LEN for HIV Tx
- Initiated two Phase 3 trials, DAYBREAK 1 and 2, evaluating LEN plus bNAbS for HIV Tx in VS PWH

3 Commercial Launches

- Bixlenvo launched in August in the U.S. as Gilead's first daily STR dedicated to PWH "switching" treatment
- Trodelvy, in combination with pembro, received European approval in 1L PD-L1+ mTNBC treatment
- Launch preparations continue ahead of anito-cel's December 23 PDUFA for 4L+ R/R MM
- Yeztugo weekly oral decision expected in February 2027; potential first QW oral regimen for PrEP

Note: YoY reflects Q326 vs. Q325 and QoQ reflects Q326 vs Q226. bNAbS - broadly neutralizing antibodies, CLE - cutaneous lupus erythematosus, ITP - immune thrombocytopenia, MM - multiple myeloma, PDUFA - Prescription Drug User Fee Act, PrEP - pre-exposure prophylaxis, PWH - people with HIV, QW - once-weekly, R/R - relapsed or refractory, STR - single tablet regimen, TCE - T cell engager, Tx - treatment, UEGW - United European Gastroenterology Week, VS - virally suppressed, Anito-cel - anitocabtagene autoleucel.




Commercial Results & Market Dynamics

Johanna Mercier
Chief Commercial &
Corporate Affairs Officer



Exceptional Base Business Performance in Q326



\$8.2B Total Product Sales excluding Veklury
+16% YoY, +8% QoQ

\$8.3B Total Product Sales
+13% YoY, +9% QoQ


\$6.2B HIV Product Sales
+18% YoY, +10% QoQ

\$860M Oncology Product Sales
+9% YoY, -2% QoQ



HIV: Strongest Year-over-Year Growth In Over 7 Years

Product Sales (\$M)



\$6.25B

Q326 Sales

+18%

Q326 Growth YoY

- YoY driven by higher average realized price, higher demand and favorable inventory dynamics
- QoQ driven by higher inventory, demand, and average realized price
- 2026 HIV growth expectations increased to 12% YoY, from +9% to 10% YoY previously



HIV Treatment: Expanding Portfolio



BIKTARVY®

bictegravir 50mg/emtricitabine 200mg/
tenofovir alafenamide 25mg tablets

Q326 sales: \$4.1B; +10% YoY, +8% QoQ


#1

Regimen for naïve &
switches across most
major markets

~53%

U.S. Treatment
Market Share

- YoY driven by higher demand and average realized price, as well as favorable inventory dynamics
- QoQ driven by inventory dynamics and demand, partially offset by lower average realized price due to channel mix
- All-time high treatment market share in the U.S.



BIXLENVO™

bictegravir 75mg / lenacapavir 50mg tablets

FDA Approved August 27, 2026

For virologically-suppressed adults

5-6%

PWH on Complex
Regimens

Up to 20%

PWH Switch HIV
Therapies Annually

- Combines bictegravir, the most prescribed integrase inhibitor, with lenacapavir, our breakthrough capsid inhibitor
- Smallest single-tablet regimen for HIV treatment
- Rapid initial uptake by people with HIV on complex regimens



HIV PrEP: Leaders in Daily Oral & Now Long-Acting

~ 2X

PrEP Sales YoY



Q326 sales: \$305M; +31% QoQ

- Now the leading injectable PrEP regimen in the U.S.
- Best-in-PrEP 12-month persistency (>70%)
- On track to deliver FY26 sales of ~\$1B

~ 14%

U.S. PrEP Market Growth YoY




Q326 sales: \$1.0B; +49% YoY, +8% QoQ

- ~80% of Descovy sales are for PrEP
- YoY driven by higher average realized price and favorable inventory dynamics
- QoQ driven by higher-than-usual inventory build and higher demand



Liver Disease: Livdelzi Leading in 2L PBC

Product Sales (\$M)



\$203M

Q326 Livdelzi Sales

>50%


2L PBC U.S Market Share

- Livdelzi +93% YoY and +21% QoQ driven by increased demand in U.S. and Europe
- Total Liver +13% YoY driven by increased demand for Livdelzi in PBC, as well as favorable pricing dynamics for HCV and HBV, partially offset by lower HCV starts
- Total Liver +6% QoQ driven by higher average realized price and inventory, partially offset by lower HCV demand



Trodelvy: Strength Across Breast Cancer Indications

Product Sales (\$M)



+42%

YoY growth in Q326

#1


2L mTNBC¹ share

- +42% YoY and +11% QoQ reflecting strong demand in both mTNBC and pre-treated HR+/HER2- mBC
- Trodelvy is first-and-only ADC approved for 1L mTNBC across PD-L1 status in the U.S. and Europe

Note: YoY reflects Q326 vs. Q325 and QoQ reflects Q326 vs Q226. Trodelvy (sacituzumab govitecan-hziy) for injection. 1. U.S. and EU. Trodelvy is indicated for 1L mTNBC in adult patients with unresectable locally advanced or metastatic TNBC, as either a single agent for patients who are not candidates for PD-(L)1 inhibitor-based therapy with no germline BRCA 1/2 pathogenic variants, or in combination with pembrolizumab for patients whose tumors express PD-L1 (CPS ≥10). 1L - first line, ADC - antibody-drug conjugate, mBC - metastatic breast cancer, mTNBC - metastatic triple-negative breast cancer.



Cell Therapy: Ongoing Anito-Cel Launch Preparations



YESCARTA®
(axicabtagene ciloleucel) Suspension for IV infusion

TECARTUS®
(brexucabtagene autoleucel) Suspension for IV infusion

>37K

Patients treated to date

>600

ATCs globally

- -18% YoY and -15% QoQ, reflecting ongoing competitive headwinds
- Anito-cel 4L+ R/R MM PDUFA December 23, 2026, launch preparations well underway



Most Robust Launch Pipeline in Gilead's History



Note: This is illustrative and subject to timing of regulatory approvals, which may not reflect actual launch outcomes. Livdelzi was granted FDA accelerated approval in August 2024. Hepcludex (bulevirtide-gmod) was granted FDA accelerated approval for the treatment of chronic HDV in adults without cirrhosis or with compensated cirrhosis. Trodelvy is indicated for 1L mTNBC in adult patients with unresectable locally advanced or metastatic TNBC, as either a single agent for patients who are not candidates for PD-(L)1 inhibitor-based therapy or in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmhp for patients whose tumors express PD-L1 (CPS ≥ 10). Anito-cel - anitocabtagene autoleucel, ISL/LEN - islatravir/lenacapavir, MM - multiple myeloma, mTNBC - metastatic triple negative breast cancer, PBC - primary biliary cholangitis, PrEP - pre-exposure prophylaxis, PWH - people with HIV, R/R - relapsed or refractory, VS - virally suppressed.



Pipeline Updates

Dietmar Berger, MD, PhD
Chief Medical Officer



Lenacapavir Unlocks Broad HIV Pipeline

★ New Disclosure

2026

2027


2028+

Treatment	Daily Oral	Bixlenvo	U.S. Launch	EC Decision 2027	
	Weekly Oral	Islatravir + Lenacapavir	Primary Endpoints Met June 2026	Launch 2027	
		Lenacapavir + GS-3242 Lenacapavir + GS-1720	Ph2 FPI Q4 2026 and early 2027		Launch 2030
	Monthly Oral	GS-3107 + INSTI	P1 GS-3107 Clinical Hold ★		Launch 2031 - 2033
	2x/Yearly Injectable	Lenacapavir + TAB + ZAB	P3 DAYBREAK-1 & -2 Initiated Q3 2026 ★		Launch 2030
		Lenacapavir + GS-3242	P2 PULSAR-1 & -2 Initiated Q2 2026 ★		Launch 2031 - 2033
PrEP	Weekly Oral	Lenacapavir		U.S. Launch February 2027	
	1x/Yearly Injectable	Lenacapavir		P3 PURPOSE 365 Update 2027	Launch 2028

Note: All launch dates are subject to regulatory approval. Timeline estimates are as of October 2026 and subject to revision. Planned data readouts and regulatory submissions not necessarily in chronological order. For non-registrational studies, data readouts listed may be interim readouts. The use of lenacapavir as shown on this slide, alone or in combination with other antiretroviral candidates, is investigational; the safety and efficacy of these uses have not been established. Islatravir + lenacapavir is being developed in collaboration with our partner, Merck. FPI - first patient in, INSTI - integrase strand transfer inhibitor, PrEP - pre-exposure prophylaxis, TAB - teropavimab, ZAB - zinlirvimab.



Oncology: Expanding our ADC Portfolio



7

ongoing clinical-stage
ADC programs

Next-generation ADC
platform offers potentially
differentiated therapies
across solid tumors

★ New Disclosure



I&I: Differentiated Mechanisms and Modalities

Inflammatory Bowel Disease	B-cell mediated	Lupus	Liver & Other Indications
Emvistegrast (α4B7) ★ P2 Data UEGW / P3 FPI 2027 Ulcerative Colitis	Gamgertamig (BCMAxCD3) P1/2 update 2H26 congress ITP	Edecesertib (IRAK4) P2 COSMIC update at ACR in November CLE	Livdelzi (PPARδ agonist) P3 IDEAL update at AASLD in November Primary Biliary Cholangitis
GS-5290 (TLP2) P2 PALEKONA Ulcerative Colitis	KITE-363 (CD19xCD20) P1 Autoimmune Diseases	Type 2 Inflammatory	GS-4571 (GLP-1) P1 Metabolic Diseases
GS-8670 (FXR Agonist) ★ P1 IBD	Anito-cel (BCMA CAR T) P1 gMG, IIM, MS	GS-5305 (CD200R) P1 Atopic Dermatitis	GS-6791 (IRAK4) P1 Rheumatoid Arthritis
GS-1384 (IL-10R) ★ P1 IBD			GS-0151 (PD-1) P1 Rheumatoid Arthritis
IL-23 Oral Program ★ Announced HCXT-2001 Acquisition			

★ New Disclosure

Notes: I&I - Inflammation and Immunology. SWIFT is an ongoing, dose-ranging, Phase 2 study evaluated the efficacy and safety of emvistegrast in participants with moderately to severely active ulcerative colitis. Gamgertamig has been granted Orphan Drug Designation and Fast Track Designation by the FDA for certain autoimmune diseases. Gilead announced the acquisition of PepStar Therapeutics' oral IL-23 program, and closing is subject to customary conditions. AASLD - American Association for the Study of Liver Diseases, ACR - American College of Rheumatology, AIHA - autoimmune hemolytic anemia, CLE - cutaneous lupus erythematosus, FPI - first patient in, gMG - generalized myasthenia gravis, IBD - inflammatory bowel disease, IIM - idiopathic inflammatory myopathies, ITP - immune thrombocytopenia, MS - multiple sclerosis, UC - ulcerative colitis, UEGW - United European Gastroenterology Week.



Cell Therapy: Upcoming Launch & Long-Term Innovation

Anito-cel in MM: Potential Launch in 4L+ R/R and Extension into Earlier Lines

iMMagine-1

4L+ R/R MM

December 23, 2026 PDUFA

iMMagine-3

2-4L R/R MM

Filing as early as 2027

iMMagine-4

TNE NDMM

Initiation expected 2027

iMMagine-6

TE MM

Initiation expected 2027

KITE-512

Phase 1

Hepatocellular Cancer

Initiation expected soon 

Autoimmune

ARC-311

Autoimmune Diseases

Anito-cel

KITE-753

PALISADES-1 & 2

2L & 3L+ R/R DLBCL

Partial clinical hold 

in vivo

Investigator Initiated Trial

Dosing initiated in Q326 in China 

HERMOSA-1 & 2

Rheumatology & Neurology

KITE-363

 New Disclosure



Key 2026 Milestones

 Completed
  Completed¹
 On Track

1H26

Program	Trial	Indication	Update	Status
ISL/LEN	ISLEND-1	QW Oral HIV Tx	Phase 3 Update	
	ISLEND-2	QW Oral HIV Tx	Phase 3 Update	
Hepcludex	MYR301	HDV	FDA Decision	

2H26

Program	Trial	Indication	Update	Status
Bixlenvo	ARTISTRY-1 & -2	QD Oral HIV Treatment	FDA Decision	
Trodelvy	ASCENT-03	1L mTNBC (PD-L1-)	FDA Decision	
	ASCENT-04	1L mTNBC (PD-L1+)	FDA Decision	
	ASCENT-GYN	A/R Endometrial Cancer	Phase 3 Update	
	EVOKE-03	1L mNSCLC (PD-L1 High, TPS $\geq$ 50%)	Phase 3 Update ¹	
Anito-cel	iMMagine-1	4L+ R/R Multiple Myeloma	FDA Decision	
Livdelzi	IDEAL	2L Primary Biliary Cholangitis	Phase 3 Update	

1. Study did not meet primary endpoint and trial was discontinued. Data presented at WCLC in September 2026. Bixlenvo (bictegravir/lenacapavir), Hepcludex (bulevirtide), Livdelzi (seladelpar), Trodelvy (sacituzumab govitecan-hziy). A/R - advanced or recurrent, HDV - hepatitis delta virus, ISL - islatravir, LEN - lenacapavir, anito-cel (anitocabtagene autoleucel), mNSCLC - metastatic non-small cell lung cancer, mTNBC - metastatic triple-negative breast cancer, PD-L1 - programmed death-ligand 1, QD - daily, QW - weekly, R/R - relapsed or refractory, TPS - tumor proportion score.




Financial Results

Andrew Dickinson
Chief Financial Officer



Q3 2026 Base Business Sales

Product Sales (\$M)



Base Business Sales +16% YoY and +8% QoQ

- YoY driven by continued growth across HIV, Trodelvy, and Livdelzi, partially offset by lower Cell Therapy
- QoQ driven by higher HIV, Liver Disease, and Trodelvy sales, partially offset by lower Cell Therapy

Total Product Sales +13% YoY and +9% QoQ

- Reflecting lower Veklury sales due to fewer COVID-19 related hospitalizations



Q3 2026 Non-GAAP Data

In millions, except percentages and per share amounts	Q325	Q326	YoY Change
COGS	\$992	\$983	(1)%
Product Gross Margin	86%	88%	165 bps
R&D	\$1,334	\$1,591	19%
Acquired IPR&D	\$170	\$18	(89)%
SG&A	\$1,351	\$1,539	14%
Non-GAAP Operating Expenses	\$2,856	\$3,148	10%
Non-GAAP Operating Income	\$3,921	\$4,168	6%
Operating Margin	50%	50%	(25) bps
Effective Tax Rate	18%	19%	149 bps
Non-GAAP Net Income	\$3,095	\$3,186	3%
Non-GAAP Diluted EPS	\$2.47	\$2.55	3%
Shares used in per share calculation-diluted	1,254	1,251	

Non-GAAP Operating Expenses


- **R&D** YoY reflecting higher compensation-accruals related to financial outperformance YTD, as well as higher clinical costs
- **SG&A** YoY primarily reflecting HIV promotional activities, in addition to legal expenses and higher compensation-accruals related to financial outperformance YTD
- **Operating Margin** was 50% in Q326 and 49% YTD, excluding acquired IPR&D associated with the Arcellx, Tubulis, and Ouro Medicines acquisitions, in the top quartile of our peer group

Non-GAAP Diluted EPS

- **Non-GAAP Diluted EPS** YoY primarily driven by higher product sales and lower acquired IPR&D expenses, partially offset by higher operating expenses



Q326 vs. Illustrative Q325 Non-GAAP Diluted EPS



- Excluding \$0.25 benefit associated with IP asset sales in Q325, Q326 non-GAAP Diluted EPS grew \$0.33 or 15% YoY



2026 Updated Guidance

	10 February 2026	7 May 2026	4 August 2026	29 October 2026
Total Product Sales	~ \$29.6B - \$30.0B	~ \$30.0B - \$30.4B	~ \$30.1B - \$30.4B	~ \$31.0B - \$31.3B
Product Sales ex-Veklury	~ \$29.0B - \$29.4B	~ \$29.4B - \$29.8B	~ \$29.8B - \$30.1B	~ \$30.7B - \$31.0B
Veklury Sales	~ \$600M	No change	~ \$300M	No change
Non-GAAP				
Product Gross Margin	~ 87.0%	No change	No change	No change
R&D Expense	Low single-digit % growth	Mid single-digit % growth	No change	Mid to high single-digit % growth
Acquired IPR&D	~ \$0.3B	~ \$11.8B	~ \$11.5B	~ \$12.9B
SG&A Expense	Mid single-digit % growth	No change	No change	High single-digit % growth
Operating Income	~ \$13.8B - \$14.3B	~ \$2.4B - \$2.9B	~ \$2.9B - \$3.3B	~ \$2.0B - \$2.4B
Effective Tax Rate	~ 20%	~ 190% - 140%	~ 140% - 115%	~ 220% - 165%
Diluted EPS	~ \$8.45 - \$8.85	~ \$(1.05) - \$(0.65)	~ \$(0.65) - \$(0.30)	~ \$(1.20) - \$(0.85)
GAAP Diluted EPS	~ \$6.75 - \$7.15	~ \$(3.25) - \$(2.85)	~ \$(3.75) - \$(3.40)	~ \$(4.40) - \$(4.05)

Base Business Guidance +10% to +11% YoY

- Raised **Base Business** guidance by \$900M, driven by strong Q3 commercial performance; up \$1.65B from start of year FY26 guidance
- Now expect HIV to grow 12% YoY (previously 9-10% YoY); continue to expect FY26 Yeztugo sales of ~\$1B


Non-GAAP Operating Expenses

- **R&D and SG&A** increase reflects higher compensation related accruals given significant outperformance YTD
- **Acquired IPR&D** increase reflects ~\$1.4B upfront payments expected in Q426, associated with the acquisition of an oral IL-23R inhibitor from PepStar Therapeutics and the Vir collaboration

Except as otherwise noted, this financial guidance excludes the impact of any expenses related to potential acquisitions or business development transactions that have not been executed, future fair value adjustments of equity securities and discrete tax charges or benefits associated with changes in tax related laws and guidelines as Gilead is unable to project such amounts. This guidance is subject to a number of risks and uncertainties. See Forward-Looking Statements on page 2. Please refer to the accompanying press release for GAAP to non-GAAP reconciliations. EPS - earnings per share, IPR&D - in process research and development, R&D - research and development, SG&A - selling, general, and administrative. YTD - year-to-date.



FY26 Illustrative Non-GAAP EPS Guidance



- ~\$9.95 per share associated with acquisitions, +\$0.80 from last quarter due to recently announced IL-23 acquisition expected to close in Q426
- Excluding FY26 acquisitions and other revenues, FY26 Illustrative non-GAAP EPS guidance of ~\$8.93 at the midpoint, up ~\$0.78 (+10%) compared to FY25 non-GAAP diluted EPS of \$8.15

Ongoing Commitment to Disciplined Capital Deployment

Capital Allocation Priorities

~\$1B

Dividends Paid in Q326

\$370M

In Shares Repurchased in Q326^{1,2}
2.6M shares at average \$139.84

- Continue to invest in our business and R&D pipeline while managing expenses
- Continue ordinary course partnerships and business development transactions
- Grow our dividend
- Repurchase shares to offset dilution and opportunistically reduce share count



Q&A



Daniel O'Day
Chairman &
Chief Executive Officer



Johanna Mercier
Chief Commercial &
Corporate Affairs Officer



Dietmar Berger, MD, PhD
Chief Medical Officer



Andrew Dickinson
Chief Financial Officer




Cindy Perettie
EVP & Head of Kite

Robust Pipeline with Upcoming Catalysts

49 Clinical programs¹

4 Clinical opt-in assets



Pipeline shown above as of Q3 2026. 1. Program count does not include potential partner opt-in programs or programs that have received both FDA and EC approval. A/R - advanced or recurrent, Anito-cel - anitocabtagene autoleucel, Axi-cel - axicabtagene ciloleucel, EC - endometrial cancer, ES- SCLC - extensive-stage small cell lung cancer, FL - follicular lymphoma, HIV - human immunodeficiency virus, HR - high risk, ISL - islatravir, LAI - long acting injectable, LAO - long acting oral, LBCL - large B-cell lymphoma, LEN - lenacapavir, MM - multiple myeloma, pembro - pembrolizumab, PrEP - pre-exposure prophylaxis, Q12M - every 12 months, Q6M - every 6 months, QD - daily, QW - weekly, R/R - relapsed or refractory, SG - sacituzumab govitecan-hziy, TAB - teropavimab, TNBC - triple-negative breast cancer, ZAB - zinzirvimab.



Viral Diseases Pipeline 1/2

★ New listing in Q3'26
● Breakthrough Therapy Designation
▲ Q3'26 Updates

Clinical Program	Indication		Phase 1	Phase 2	Phase 3	Filed	Q3'26 Updates	
HIV Prevention								
Yeztugo® (lenacapavir)	HIV PrEP LAO QW		sNDA submitted					
Lenacapavir (PURPOSE 365)	HIV PrEP LAI Q12M							
HIV Treatment								
Bixlenvo® (ARTISTRY-1 & -2)	HIV Oral QD	▲	NDA approved					FDA approval granted
Islatravir/lenacapavir (ISLEND-1 &-2) ¹	HIV LAO QW	▲						
LEN + TAB + ZAB (DAYBREAK 1 & 2)	HIV LAI Q6M	▲ ●						P2 → P3
HIV INSTI (GS-3242) + lenacapavir (PULSAR 1 & 2) ²	HIV LAI Q6M	▲						P1 → P2
HIV INSTI (GS-3242) + lenacapavir	HIV LAO QW	▲						P1 → P2
HIV capsid inhibitor (GS-3107) ³	HIV LAO QM	▲	Clinical hold					Clinical hold
HIV Cure								
Teropavimab + zinlirvimab	HIV Cure							
Vesatolimod	HIV Cure							
HIV bispecific T-cell engager (GS-8588)	HIV Cure							
Targeted IL-15 (GS-0415)	HIV Cure	★						P1 FPI

Pipeline shown above as of Q3 2026. Removed programs: HIV INSTI/capsid inhibitor (GS-1720/GS-4182) (WONDERS-1) for HIV treatment. HIV INSTI (GS-1219) Phase 1 for HIV treatment. 1. Subject to Gilead and Merck co-development and co-commercialization agreement. 2. GS-3242 + lenacapavir is also being investigated in HIV LAI Q4M. 3. Program timelines pending resolution of the GS-3107 clinical hold. FDA - food and drug administration, HIV - human immunodeficiency virus, INSTI - integrase strand transfer inhibitor, LAI - long-acting injectable, LAO - long-acting oral, LEN - lenacapavir, NDA - new drug application, PrEP - pre-exposure prophylaxis, Q12M - every 12 months, Q6M - every 6 months, QD - daily, QW - weekly, sNDA - supplemental new drug application, TAB - teropavimab, ZAB - zinlirvimab.



Viral Diseases Pipeline 2/2

★ New listing in Q3'26
 ● Breakthrough Therapy Designation
 ▲ Q3'26 Updates

Clinical Program	Indication	Phase 1	Phase 2	Phase 3	Filed	Q3'26 Updates
HDV						
HDV pre-S1 nAb (GS-4321)	HDV	<div><div></div></div>				
HBV Cure						
HBV therapeutic vaccine (GS-2829 + GS-6779)	HBV Cure	<div><div></div></div>				
HSV						
HSV HPI (GS-1179)	HSV	<div><div></div></div>				
Infectious Disease						
Coronavirus mPro Inhibitor (GS-1701)	NEVPP	<div><div></div></div>				
Opt-ins						
Assembly Biosciences	HDV	1 clinical stage program				



Cell Therapy Pipeline

★ New listing in Q3'26
● Breakthrough Therapy Designation
▲ Q3'26 Updates
R RMAT Designation

Clinical Program	Indication		Phase 1	Phase 2	Phase 3	Filed	Q3'26 Updates
Lymphoma							
Axicabtagene ciloleucel (ZUMA-22)	2L+ HR FL						
Axicabtagene ciloleucel (ZUMA-23)	1L HR LBCL						
CD19/CD20 bicistronic (KITE-753) (PALISADES-2) ^{1, 2}	2L DLBCL	▲ R			Clinical hold		Clinical hold
CD19/CD20 bicistronic (KITE-753) (PALISADES-1) ^{1, 2}	3L+ R/R DLBCL	▲ R		Clinical hold			Clinical hold
Multiple Myeloma							
Anitocabtagene autoleucel (iMMagine-1)	4L+ R/R MM					BLA Filed	
Anitocabtagene autoleucel (iMMagine-3)	2-4L R/R MM						
Autoimmune Diseases							
CD19/CD20 bicistronic (KITE-363) (HERMOSA-1)	Rheumatology						
CD19/CD20 bicistronic (KITE-363) (HERMOSA-2)	Neurology						
Anitocabtagene autoleucel (ARC-311)	Autoimmune Diseases						

Pipeline shown above as of Q3 2026. Removed programs: Brexucabtagene autoleucel (ZUMA-4) data was submitted 15 SEP 2026, fulfilling the EU Pediatric Investigation Plan (PIP). 1. Manufacturing innovation. 2. Programs pending resolution of KITE-753 clinical hold. ALL - acute lymphocytic leukemia, BLA - biological license application, DLBCL - diffuse large B-cell lymphoma, FL - follicular lymphoma, HR - high risk, LBCL - large B cell lymphoma, MM - multiple myeloma, NHL - non-Hodgkin's lymphoma, R/R - relapsed or refractory, RMAT - regenerative medicine advanced therapy.



Oncology Pipeline 1/2

★ New listing in Q3'26 ▲ Q3'26 Updates
● Breakthrough Therapy Designation

Clinical Program	Indication	Phase 1	Phase 2	Phase 3	Filed	Q3'26 Updates
Breast						
Sacituzumab govitecan-hziy + pembrolizumab (ASCENT-05)	High risk adjuvant TNBC	<div></div>				
Lung & Thoracic						
Sacituzumab govitecan-hziy (EVOKE-SCLC-04)	2L ES-SCLC	●	<div></div>			
Gynecology						
Sacituzumab govitecan-hziy (ASCENT-GYN-01) ¹	A/R EC	<div></div>				
NaPi2b ADC (GS-8824) (NAPISTAR 1-01) ²	2L+ PROC	<div></div>				
NaPi2b ADC (GS-8824) (NAPISTAR 1-03) ²	A/R EC	★	<div></div>			
NaPi2b ADC (GS-8824) (NAPISTAR 1-02) ²	2L+ PSOC	<div></div>				
Advanced Cancers						
Efarindodekin Alfa ³	Advanced Cancers	<div></div>				
5T4 ADC (GS-8823) ⁴	Advanced Cancers	<div></div>				
Anti -IL-18BP (GS-0321) ⁵	Advanced Cancers	<div></div>				
GS-1206	Advanced Cancers	★	<div></div>			

Pipeline shown above as of Q3 2026. Removed programs: Denikitug Phase 2 study in mCRC. 1. In collaboration with the GOG Foundation (GOG) and European Network of Gynecological Oncological Trial Groups (ENGOT). 2. Previously TUB-40. 3. Operationalized by Xilio, previously TX301. 4. Previously TUB-30. 5. Operationalized by Compugen. 5T4 - trophoblast glycoprotein, A/R - advanced or recurrent, ADC - antibody drug conjugate, EC - endometrial cancer, ES-SCLC - extensive stage - small cell lung cancer, FPI - first patient in, IL-18 BP - interleukin 18 binding protein, NaPi2b - Sodium-dependent phosphate transport protein 2B, PROC - platinum-resistant ovarian cancer, PSOC - platinum-sensitive ovarian cancer, TNBC - triple-negative breast cancer.



Oncology Pipeline 2/2

★ New listing in Q3'26

▲ Q3'26 Updates

● Breakthrough Therapy Designation

Clinical Program	Indication	Phase 1	Phase 2	Phase 3	Filed	Q3'26 Updates
Advanced Cancers						
MAT2A inhibitor (GS-2426)	Advanced Cancers	<div></div>				
PARP1 inhibitor (GS-0201)	Advanced Cancers	<div></div>				
PRMT5 Inhibitor (GS-5319)	Advanced Cancers	<div></div>				
Opt-ins						
Arcus	Advanced Cancers	2 clinical stage programs				
MacroGenics	Advanced Cancers	1 clinical stage program				



Inflammatory Diseases Pipeline

★ New listing in Q3'26
● Breakthrough Therapy Designation
▲ Q3'26 Updates

Clinical Program	Indication	Phase 1	Phase 2	Phase 3	Filed	Q3'26 Updates
Lupus						
Edecisertib (COSMIC)	Lupus	<div></div>				
Inflammatory Bowel Disease						
Tilpisertib fosmecarbil (PALEKONA)	IBD	<div></div>				
Emvistegrast (SWIFT) ¹	IBD	<div></div>				
FXR agonist (GS-8670)	IBD	<div></div>				
Inflammatory Diseases						
Gamgertamig ²	Inflammatory Diseases	<div></div>				
CD200R agonist (GS-5305)	Inflammatory Diseases	<div></div>				
IL-10R VHH (GS-1384)	Inflammatory Diseases	★	<div></div>			P1 FPI
IRAK4 Degradar (GS-6791)	Inflammatory Diseases	<div></div>				
PD1 agonist (GS-0151)	Inflammatory Diseases	<div></div>				
Metabolic Disease						
GLP-1R agonist (GS-4571)	Metabolic Disease	<div></div>				

Pipeline shown above as of Q3 2026. 1. Previously GS-1427. 2. Gamgertamig is being investigated in autoimmune hemolytic anemia (AIHA), immune thrombocytopenia (ITP), and other inflammatory diseases. FXR - farnesoid X receptor, GLP-1 - glucagon-like peptide-1, IBD - inflammatory bowel disease, IL-10R VHH - Interleukin-10 receptor variable heavy chain of heavy-chain-only antibody, IRAK4 - interleukin-1 receptor-associated kinase 4, PD1 - programmed cell death protein 1.



GAAP to Non-GAAP Reconciliation of Outstanding Adjusted Debt and Adjusted EBITDA

in billions where applicable	As of				
	Sep 30, 2025	Dec 31, 2025	Mar 31, 2026	Jun 30, 2026	Sep 30, 2026
Total Debt, net	\$24.94	\$24.94	\$22.17	\$26.25	\$26.23
Debt Discounts, Premiums and Issuance Costs	0.18	0.17	0.17	0.18	0.18
Liability related to sale of future royalties ¹	(1.12)	(1.11)	(1.09)	(1.08)	(1.06)
Total Adjusted Debt¹	\$24.00	\$24.00	\$21.25	\$25.35	\$25.35
	Twelve Months Ended				
	Sep 30, 2025	Dec 31, 2025	Mar 31, 2026	Jun 30, 2026	Sept 30, 2026
Net Income attributable to Gilead	\$8.11	\$8.51	\$9.22	(3.24)	(3.86)
Add: Interest Expense ² & Other (Income) expense, net	0.60	0.23	(0.36)	(0.54)	0.17
Add: Tax	1.78	1.29	1.51	1.28	1.33
Add: Depreciation	0.38	0.37	0.38	0.37	0.41
Add: Amortization	2.39	2.39	2.39	2.39	2.40
Add: Initial costs of externally developed IPR&D projects ³	0.43	0.81	0.64	11.72	11.58
Add: Impairments	0.19	0.59	0.59	2.15	2.15
Adjusted EBITDA⁴	\$13.88	\$14.18	\$14.37	\$14.14	\$14.18
Adjusted Debt to Adjusted EBITDA ratio⁴	~1.73x	~1.69x	~1.48x	~1.79x	~1.79x

1. Adjusted debt excludes a funding agreement with RPI Finance Trust that was assumed as part of our acquisition of Immunomedics under which Immunomedics received cash in exchange for perpetual, tiered royalty payments on worldwide sales of Trodelvy.

2. Total interest expense and amortization from all issued debt is expected to be \$1 billion for the full year 2026. We retain the flexibility to refinance or to repay maturing debt.

3. Represents the initial costs of externally developed IPR&D projects with no alternative future use, acquired directly in a transaction other than a business combination, including upfront payments related to various collaborations and the initial costs of rights to IPR&D projects.

4. Adjusted EBITDA and Adjusted Debt to Adjusted EBITDA ratio are non-GAAP performance measures used by our investors and analysts to assess the overall operating performance in the context of financial leverage.

